Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review.

IF 4.7 2区医学 Q1 ONCOLOGY Current Oncology Reports Pub Date : 2024-10-01 Epub Date: 2024-07-13 DOI:10.1007/s11912-024-01579-6

Varun Bhasin, Azin Vakilpour, Marielle Scherrer-Crosbie

{"title":"Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review.","authors":"Varun Bhasin, Azin Vakilpour, Marielle Scherrer-Crosbie","doi":"10.1007/s11912-024-01579-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: The aim of this review is two-fold: (1) To examine the mechanisms by which statins may protect from anthracycline-induced cardiotoxicity and (2) To provide a comprehensive overview of the existing clinical literature investigating the role of statins for the primary prevention of anthracycline-induced cardiotoxicity.Recent findings: The underlying cardioprotective mechanisms associated with statins have not been fully elucidated. Key mechanisms related to the inhibition of Ras homologous (Rho) GTPases have been proposed. Data from observational studies has supported the beneficial role of statins for the primary prevention of anthracycline-induced cardiotoxicity. Recently, several randomized controlled trials investigating the role of statins for the primary prevention of anthracycline-induced cardiotoxicity have produced contrasting results. Statins have been associated with a lower risk of cardiac dysfunction in cancer patients receiving anthracyclines. Further investigation with larger randomized control trials and longer follow-up periods are needed to better evaluate the long-term role of statin therapy and identify the subgroups who benefit most from statin therapy.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":null,"pages":null},"PeriodicalIF":4.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480194/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01579-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The aim of this review is two-fold: (1) To examine the mechanisms by which statins may protect from anthracycline-induced cardiotoxicity and (2) To provide a comprehensive overview of the existing clinical literature investigating the role of statins for the primary prevention of anthracycline-induced cardiotoxicity.

Recent findings: The underlying cardioprotective mechanisms associated with statins have not been fully elucidated. Key mechanisms related to the inhibition of Ras homologous (Rho) GTPases have been proposed. Data from observational studies has supported the beneficial role of statins for the primary prevention of anthracycline-induced cardiotoxicity. Recently, several randomized controlled trials investigating the role of statins for the primary prevention of anthracycline-induced cardiotoxicity have produced contrasting results. Statins have been associated with a lower risk of cardiac dysfunction in cancer patients receiving anthracyclines. Further investigation with larger randomized control trials and longer follow-up periods are needed to better evaluate the long-term role of statin therapy and identify the subgroups who benefit most from statin therapy.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

他汀类药物用于蒽环类药物心脏毒性的一级预防：全面回顾。

综述目的：本综述有两个目的：(1) 研究他汀类药物可预防蒽环类药物诱发的心脏毒性的机制；(2) 全面概述现有的临床文献，研究他汀类药物在初级预防蒽环类药物诱发的心脏毒性中的作用：他汀类药物的心脏保护机制尚未完全阐明。有人提出了与抑制 Ras 同源（Rho）GTP 酶有关的关键机制。来自观察性研究的数据支持他汀类药物在初级预防蒽环类药物引起的心脏毒性方面的有益作用。最近，几项随机对照试验对他汀类药物在初级预防蒽环类诱导的心脏毒性方面的作用进行了调查，结果却截然不同。他汀类药物可降低接受蒽环类药物治疗的癌症患者出现心脏功能障碍的风险。为了更好地评估他汀类药物治疗的长期作用，并确定从他汀类药物治疗中获益最多的亚组，还需要通过更大规模的随机对照试验和更长的随访期进行进一步调查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.